Reliable choice in treatment of acquired microbial resistance. Especially active against gram-negative (-) bacteria. Most active against Pseudomonas aeruginosa, Acinetobacter baumannii, Citrobacter spp. Used parenterally in treatment of serious infections of lower respiratory tract and urinary system when widely used systemic antibiotics are ineffective because of development of bacterial resistance. Inhalational administration is recommended for patients with mucoviscidosis.
A highly potent carbapenem antibiotic drug. Active against gram-positive (+) and gram-negative (-) aerobic and anaerobic bacteria. Several times more active against Pseudomonas aeruginosa compared to meropenem and imipenem/cilastatin. Used in treatment of hospital-acquired (nosocomial) pneumonia, including ventilator-associated pneumonia; complicated intraabdominal infections; complicated infections of urinary system, including complicated and uncomplicated pyelonephritis, particularly pyelonephritis with accompanying bacteremia.
An ultra-wide range of antibacterial activity includes practically all significant gram-positive (+) and gram-negative (-) aerobic and anaerobic microorganisms. Non-neurotoxic. Used for de-escalation therapy of serious infections of lower respiratory tract, intraabdominal infections, gynecological infections, skin and soft tissue infections, meningitis, septicemia, empiric treatment in patients with neutropenia, as monotherapy or in combination with antiviral or antifungal pharmaceutical products.
“Gold standard” of monotherapy of serious infections in inpatient settings.
Active against a wide range of gram-positive (+) and gram-negative aerobic bacteria, majority of anaerobic bacteria.
Used in therapy of serious polymicrobic infections of lower respiratory tract, urinary system infections, intraabdominal infections, gynecological infections, skin and soft tissue infections, bone and joint infections, endocarditis.
New highly effective glycopeptide antibiotic for systemic use with bactericidal activity against a wide range of gram-positive (+) bacteria, multiresistant nosocomial strains, including VanB-phenotype VRE. It can be administered once daily intramuscularly or intravenously as a bolus injection. The antibiotic has low toxicity and favorable tolerability. It is used in treatment of serious respiratory and urinary tract infections, skin and soft tissue infections, bone and joint infections, septicemia, endocarditis, peritonitis, infectious colitis.
First antibiotic of the glycopeptide group. Highly active against a wide range of gram-positive (+) microorganisms, including methicillin-resistant strains.
Used in treatment of endocarditis, sepsis, skin and soft tissue infections, bone and joint infections (including osteomyelitis), CNS infections (including meningitis), infections of lower respiratory tract, pseudomembranous colitis, enterocolitis.
Cephalosporins Generation III
“Protected” third-generation cephalosporin in combination with β-lactamase inhibitor. Wide range of antibacterial activity against clinically significant gram-positive (+) and gram-negative (-) aerobic and anaerobic microorganisms.
Used as monotherapy for treatment of serious infections of upper and lower respiratory tract, peritonitis, cholecystitis, cholangitis and other intraabdominal infections, infections of genital organs, including gonorrhea. Well-tolerated when administered intravenously.